Hanmi and Celltrion produce oral COVID-19 treatments developed by MSD and supply them to underdeveloped countries. According to the industry on the 20th, Hanmi and Celltrion have completed a license-in contract with the MPP for the production of generic drugs for Molnupiravir (Lagevrio) treatment for COVID-19.

The license contract is based on the granting of a non-exclusive license by MSD, the original developer of "Molnupiravir," that allows the sale of mid- to low-income countries through MPP, an international institution, to expand access to COVID-19 treatments. A number of pharmaceutical companies around the world submitted letters of intent to select licensees, and only 27 companies were given license